Interruption of the canine estrous cycle with a low and a high dose of the GnRH antagonist, acyline

Theriogenology

Volumn 71, Issue 3, 2009, Pages 408-411

  Valiente, C ^a   Romero, G García ^a   Corrada, Y ^a   de la Sota, P E ^a   Hermo, G ^a   Gobello, C ^a  

^a UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

Author keywords

Acyline; Dog; Estrus; Estrus suppression; GnRH analog; Proestrus

Indexed keywords

ACYLINE; GONADORELIN; OLIGOPEPTIDE;

ANIMAL; ANOVULATION; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DRUG ANTAGONISM; DRUG EFFECT; ESTRUS CYCLE; FEMALE; LD 50; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; ANOVULATION; DOGS; ESTROUS CYCLE; FEMALE; GONADOTROPIN-RELEASING HORMONE; LETHAL DOSE 50; OLIGOPEPTIDES;

ANIMALIA; CANIDAE; CANIS FAMILIARIS;

EID: 57849091648     PISSN: 0093691X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.theriogenology.2008.08.007     Document Type: Article

References (18)

1. Clinical use of progestins in bitches and queens: a review. In: Concannon PW, England G, Verstegen J, Linde-Forsberg C (Eds.). Recent advances in small animal reproduction. International Veterinary Information Service (www.ivis.org) 2003, A1206.0903.
2. Gobello C. New GnRH analogs in canine reproduction: a review. Anim Reprod Sci 100 (2007) 1-13
3. Karten M.J., and Rivier J.E. Gonadotropin releasing hormone analog design. Structure function studies toward the development of agonists and antagonists, rationale and perspective. Endocr Rev 7 (1986) 44-66
4. Vickery B.H. Nestor JJ LHRH analogues, development and mechanism of action. Sem Reprod Endocrinol 5 (1987) 353-370
5. Heber D., Dobson R., Swerdloff R.S., Channabasavaiah K., and Stewart J.M. Pituitary receptor site blockade by a gonadotropin-releasing antagonist in vivo: mechanism of action. Science 216 (1982) 420-421
6. Vickery B.H., Mc Rae G.I., Goodpasture J.C., and Sanders L.M. Use of potent LHRH analogues for chronic contraception and pregnancy termination. J Reprod Fertil 39 (1989) 175-187
7. Herbst K.L. Gonadotropin-releasing hormone antagonists. Curr Opin Pharmacol 3 (2003) 1-7
8. Valiente C., Corrada Y., de la Sota P.E., Galassi Gerez P., and Gobello C. Effect of the GnRH antagonist, acyline, on canine testicular characteristics. Theriogenology 68 (2007) 687-692
9. Herbst K.L., Anawalt B.D., Amory J.K., and Bremner W.J. Acyline: the first study in humans of a potent, new gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab 87 (2002) 3215-3220
10. Gobello C., Hermo G., Rodríguez R., Tortora M., and Corrada Y. Use of the GnRH antagonist, acyline, on estrous cycle interruption in the bitch: a preliminary report. Theriogenology 64 (2005) 809 (abstract)
11. Herbst K.L., Coviello A.D., Page S., Amory J.K., Anawalt B.D., and Bremner W.J. A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. J Clin Endocrinol Metab 89 (2004) 5959-5965
12. Olson P.N., Thrall M.A., Wykes P.M., and Nett T.M. Vaginal cytology. Part I. A useful tool for staging the canine estrous cycle. Comp Cont Educ Pract 6 (1984) 288-297
13. Nishiyama T., Tsumagari S., and Takeishi M. Shrinkage in the horizontal dimensions of the vulva (vulvar shrinkage) as an indication of standing heat in the beagle. J Am Anim Hosp Assoc 36 (2000) 556-560
14. Mc Cann J.P., and Temple M. Biology and endocrinology of ovulation, pregnancy and parturition in the dog. J Reprod Fertil (Suppl) 39 (1989) 3-25
15. ®. User's guide, Version 6. 4th Edition (1989), SAS Institute Inc., Cary, NC, USA p. 189
16. Johnston S.D., Root Kustritz M.V., and Olson P.N. Canine and feline theriogenology (2001), Saunders WB, Philadelphia p. 592
17. Pelican K.M., Brown J.L., Wildt D.E., Ottinger M.A., and Howard J.G. Short term suppression of follicular recruitment and spontaneous ovulation in the cat using levonorgestrel versus a GnRH antagonist. Gen Comp Endocrinol 144 (2005) 110-121
18. Tarlatzis B.C., and Bili H. Safety of GnRH agonists and antagonists. Expert Opin Drug Safety 3 (2004) 39-46